Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
Frequent AEs associated with PI3K/AKT pathway inhibition occurred early and were manageable. The low rate of treatment discontinuations suggests that, when appropriately managed, these AEs do not pose a challenge to clinical benefit.
Authors
- Hiroji Iwata (ORCID: https://orcid.org/0000-0002-0242-4718)
- F. Dalenc
- S. Morales Murillo
- Sacha J. Howell (ORCID: https://orcid.org/0000-0001-8141-6515)
- Петр Владимирович Криворотько (ORCID: https://orcid.org/0000-0002-4898-9159)
- Joohyuk Sohn (ORCID: https://orcid.org/0000-0002-2303-2764)
- H.S. Rugo
- Komal L. Jhaveri (ORCID: https://orcid.org/0000-0003-0472-1254)
- Y.H. Park
- Júlia Alves Côrtes
- Celina M. D’Cruz
- Henry Gómez (ORCID: https://orcid.org/0000-0003-2660-1843)
- M Khatun (ORCID: https://orcid.org/0000-0002-8992-188X)
- Zbigniew Ireneusz Nowecki (ORCID: https://orcid.org/0000-0001-7706-8191)
- Nicholas C. Turner (ORCID: https://orcid.org/0000-0001-8937-0873)
- Meena Okera (ORCID: https://orcid.org/0000-0002-0027-5798)
- Jessica M. Logan (ORCID: https://orcid.org/0000-0003-4046-6908)
- Lyudmila Zhukova (ORCID: https://orcid.org/0000-0003-4848-6938)
- Sibylle Loibl
- Sarah Yousef (ORCID: https://orcid.org/0000-0002-2333-1086)
- M. Oliveira
- Masakazu Toi (ORCID: https://orcid.org/0000-0003-1488-9958)
- Xingjiang Hu (ORCID: https://orcid.org/0000-0002-8579-625X)
- K.M. Twomey
Institutions
- AstraZeneca (United Kingdom) (GB)
- Institute of Cancer Research (GB)
- Emek Medical Center (IL)
- Moscow Clinical Scientific Center (RU)
- Fudan University Shanghai Cancer Center (CN)
- Institute of Oncology NN Petrov (RU)
- Royal Marsden Hospital (GB)
- Institute for Research in Biomedicine (ES)
- Institut Claudius Regaud (FR)
- Aichi Cancer Center (JP)
- Centre for Cancer Biology (AU)
- Kyoto University Hospital (JP)
- AstraZeneca (United States) (US)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103697
- Citations
- 14
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 5.87
Funders
- AstraZeneca
- Astex Pharmaceuticals